Included under terms of UK Non-commercial Government License.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Headline
The study found that evidence on the measurement of the fraction of exhaled nitric oxide (FeNO) in the breath of patients with symptoms of asthma is difficult to interpret or inconclusive with regard to its role in diagnosis or management but that economic analysis indicates that FeNO monitoring could have value in diagnostic and management settings.
Abstract
Background:
High fractions of exhaled nitric oxide (FeNO) in the breath of patients with symptoms of asthma are correlated with high levels of eosinophils and indicate that a patient is likely to respond to inhaled corticosteroids. This may have a role in the diagnosis and management of asthma.
Objective:
To assess the diagnostic accuracy, clinical effectiveness and cost-effectiveness of the hand-held electrochemical devices NIOX MINO® (Aerocrine, Solna, Sweden), NIOX VERO® (Aerocrine) and NObreath® (Bedfont Scientific, Maidstone, UK) for the diagnosis and management of asthma.
Data sources:
Systematic searches were carried out between March 2013 and April 2013 from database inception. Databases searched included MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of Effects, Science Citation Index Expanded and Conference Proceedings Citation Index – Science. Trial registers such as ClinicalTrials.gov and the metaRegister of Controlled Trials were also searched in March 2013. All searches were updated in September 2013.
Review methods:
A rapid review was conducted to assess the equivalence of hand-held and chemiluminescent FeNO monitors. Systematic reviews of diagnostic accuracy and management efficacy were conducted. A systematic review of economic analyses was also conducted and two de novo health economic models were developed. All three reviews were undertaken according to robust high-quality methodology.
Results:
The rapid review (27 studies) found varying levels of agreement between monitors (Bland–Altman 95% limits of agreement up to ±10 parts per billion), with better agreement at lower FeNO values. Correlation was good (generally r > 0.9). The diagnostic accuracy review identified 22 studies in adults (all ages) and four in children. No studies used NObreath or NIOX VERO and seven used NIOX MINO. Estimates of diagnostic accuracy varied widely. FeNO used in combination with another test altered diagnostic accuracy only slightly. High levels of heterogeneity precluded meta-analysis. Limited observations included that FeNO may be more reliable and useful as a rule-in than as a rule-out test; lower cut-off values in children and in smokers may be appropriate; and FeNO may be less reliable in the elderly. The management review identified five randomised controlled trials in adults, one in pregnant asthmatics and seven in children. Despite clinical heterogeneity, exacerbation rates were lower in all studies but not generally statistically significantly so. Effects on inhaled corticosteroid (ICS) use were inconsistent, possibly because of differences in management protocols, differential effectiveness in adults and children and differences in population severity. One UK diagnostic model and one management model were identified. Aerocrine also submitted diagnostic and management models. All had significant limitations including short time horizons and the selective use of efficacy evidence. The de novo diagnostic model suggested that the expected difference in quality-adjusted life-year (QALY) gains between diagnostic options is likely to be very small. Airway hyper-responsiveness by methacholine challenge test is expected to produce the greatest QALY gain but with an expected incremental cost-effectiveness ratio (ICER) compared with FeNO (NObreath) in combination with bronchodilator reversibility of £1.125M per QALY gained. All remaining options are expected to be dominated. The de novo management model indicates that the ICER of guidelines plus FeNO monitoring using NObreath compared with guidelines alone in children is expected to be approximately £45,200 per QALY gained. Within the adult subgroup, FeNO monitoring using NObreath compared with guidelines alone is expected to have an ICER of approximately £2100 per QALY gained. The results are particularly sensitive to assumptions regarding changes in ICS use over time, the number of nurse visits for FeNO monitoring and duration of effect.
Conclusions:
Limitations of the evidence base impose considerable uncertainty on all analyses. Equivalence of devices was assumed but not assured. Evidence for diagnosis is difficult to interpret in the context of inserting FeNO monitoring into a diagnostic pathway. Evidence for management is also inconclusive, but largely consistent with FeNO monitoring resulting in fewer exacerbations, with a small or zero reduction in ICS use in adults and a possible increased ICS use in children or patients with more severe asthma. It is unclear which specific management protocol is likely to be most effective. The economic analysis indicates that FeNO monitoring could have value in diagnostic and management settings. The diagnostic model indicates that FeNO monitoring plus bronchodilator reversibility dominates many other diagnostic tests. FeNO-guided management has the potential to be cost-effective, although this is largely dependent on the duration of effect. The conclusions drawn from both models require strong technical value judgements with respect to several aspects of the decision problem in which little or no empirical evidence exists. There are many potential directions for further work, including investigations into which management protocol is best and long-term follow-up in both diagnosis and management studies.
Study registration:
This study is registered as PROSPERO CRD42013004149.
Funding:
The National Institute for Health Research Health Technology Assessment programme.
Contents
- Plain English summary
- Scientific summary
- Chapter 1. Background
- Chapter 2. Definition of the decision problem
- Chapter 3. Clinical review
- Chapter 4. The cost-effectiveness of FeNO testing for the diagnosis and management of asthma
- Introduction
- Aims and objectives of the health economic assessment of FeNO testing
- Review of existing evidence relating to the cost-effectiveness of FeNO testing for the diagnosis and management of asthma
- Development of two de novo models to estimate the cost-effectiveness of FeNO testing for the diagnosis and management of asthma
- De novo model results
- Discussion
- Chapter 5. Assessment of factors relevant to the NHS and other parties
- Chapter 6. Discussion
- Acknowledgements
- References
- Appendix 1 Search strategies for the clinical review
- Appendix 2 Clarification of the scope: communication with specialist committee member clinicians
- Appendix 3 Data extraction forms
- Appendix 4 Quality assessment scoring criteria
- Appendix 5 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram
- Appendix 6 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram
- Appendix 7 Table of study characteristics for non-relevant adult diagnostics
- Appendix 8 Table of the highest sum of sensitivity and specificity, highest sensitivity and highest specificity for non-relevant studies
- Appendix 9 Table detailing the reference standards used in relevant adult diagnostic studies
- Appendix 10 Table detailing the inclusion and exclusion criteria of the studies considered of most relevance to the review
- Appendix 11 Table of results for all diagnostic studies in adults
- Appendix 12 Table of results for all diagnostic studies in children
- Appendix 13 MEDLINE search strategies for the economic review
- Glossary
- List of abbreviations
Article history
The research reported in this issue of the journal was commissioned and funded by the HTA programme on behalf of NICE as project number 12/60/01. The protocol was agreed in March 2013. The assessment report began editorial review in September 2013 and was accepted for publication in October 2014. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
Declared competing interests of authors
Professor Ian Pavord received speaker and travel fees from GlaxoSmithKline, Astra Zeneca, Napp and Boehringer Ingelheim and speaker fees from Aerocrine and Boston Scientific, all outside this work. Dr Rod Lawson received research support in the form of a grant from GSK and Novartis for diagnostic imaging, personal fees from GlaxoSmithKline and Novartis for advisory board meetings and educational meetings and personal fees from AstraZeneca, Almirall and Boehringer Ingelheim for educational meetings, all outside this work.
- NLM CatalogRelated NLM Catalog Entries
- Comparison of two exhaled nitric oxide analyzers: the NIOX MINO hand-held electrochemical analyzer and the NOA280i stationary chemiluminescence analyzer.[Respirology. 2012]Comparison of two exhaled nitric oxide analyzers: the NIOX MINO hand-held electrochemical analyzer and the NOA280i stationary chemiluminescence analyzer.Kim SH, Moon JY, Kwak HJ, Kim SI, Park DW, Kim JW, Kim TH, Sohn JW, Shin DH, Park SS, et al. Respirology. 2012 Jul; 17(5):830-4.
- Comparison of fractional exhaled nitric oxide levels measured by different analyzers produced by different manufacturers.[J Asthma. 2020]Comparison of fractional exhaled nitric oxide levels measured by different analyzers produced by different manufacturers.Saito J, Kikuchi M, Fukuhara A, Sato S, Rikimaru M, Suzuki Y, Uematsu M, Fukuhara N, Kawamata T, Umeda T, et al. J Asthma. 2020 Nov; 57(11):1216-1226. Epub 2019 Jul 22.
- An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom.[Allergy. 2009]An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom.Price D, Berg J, Lindgren P. Allergy. 2009 Mar; 64(3):431-8. Epub 2009 Jan 29.
- Review Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.[Health Technol Assess. 2012]Review Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J. Health Technol Assess. 2012; 16(37):1-253, iii-iv.
- Review Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.[Health Technol Assess. 2013]Review Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C. Health Technol Assess. 2013 Nov; 17(52):1-342.
- Measurement of exhaled nitric oxide concentration in asthma: a systematic review...Measurement of exhaled nitric oxide concentration in asthma: a systematic review and economic evaluation of NIOX MINO, NIOX VERO and NObreath
Your browsing activity is empty.
Activity recording is turned off.
See more...